Phase 1/2 Trial of AFTX-201 in BAG3-Associated Dilated Cardiomyopathy Initiated
Affinia Therapeutics has launched Phase 1/2 trial for AFTX-201 targeting BAG3-associated dilated cardiomyopathy.
Asset / Drug
Drug and asset intelligence for AFTX-201 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Gene Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.